(Q36848280)

16 August 2017

1 reference

title

How should we manage patients with non-alcoholic fatty liver disease in 2007? (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

16 August 2017

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

1 reference

5

Geoffrey C Farrell

1 reference

16 August 2017

Henry L-Y Chan

1

1 reference

16 August 2017

H Janaka de Silva

2

1 reference

16 August 2017

Nancy W-Y Leung

3

1 reference

16 August 2017

Seng-Gee Lim

4

1 reference

16 August 2017

Asia-Pacific Working Party on NAFLD

6

1 reference

16 August 2017

1 June 2007

1 reference

Journal of Gastroenterology and Hepatology

16 August 2017

1 reference

16 August 2017

22

1 reference

16 August 2017

6

1 reference

16 August 2017

801-808

1 reference

The utility of radiological imaging in nonalcoholic fatty liver disease.

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

AGA technical review on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Clinical features and natural history of nonalcoholic steatosis syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

An evaluation of candidate definitions of the metabolic syndrome in adult Asian Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Fatty liver and the metabolic syndrome among Shanghai adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Prevalence of the metabolic syndrome among Korean adults according to the criteria of the International Diabetes Federation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Dietary composition and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Non-alcoholic fatty liver disease and the metabolic syndrome: effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Steatosis recovery after treatment with a balanced sunflower or olive oil-based diet: involvement of perisinusoidal stellate cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Time course of the development of non-alcoholic hepatic steatosis in response to high-fat diet-induced obesity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Exercise and risk factors associated with metabolic syndrome in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Therapeutic effects of restricted diet and exercise in obese patients with fatty liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Statins and hepatotoxicity: focus on patients with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

The effect of obesity surgery on obesity comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2007.04977.X

10.1111/J.1440-1746.2007.04977.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference